# Laurence Albiges

Source: https://onco.cc/people/laurence-albiges/  
OnCo record `laurence-albiges` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.

## Summary

Laurence Albiges was a lead investigator of CheckMate 214 (nivolumab plus ipilimumab) and of the LITESPARK trials that established belzutifan, the first HIF-2 alpha inhibitor, for previously treated clear-cell renal cell carcinoma. She led the CheckMate 214 long-term follow-up analyses and chairs the ESMO renal cancer guideline group. She heads medical oncology at Gustave Roussy.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: rcc; hif2a; guidelines
- Role: Head of the Department of Medical Oncology, Gustave Roussy
- Specialisms: Renal cell carcinoma; Immunotherapy; HIF-2 alpha inhibition; Treatment sequencing

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [HIF-2α](https://onco.cc/targets/hif2a/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- trials: [CheckMate 214](https://onco.cc/trials/checkmate-214/), [LITESPARK-005](https://onco.cc/trials/litespark-005/)
- journals: [ESMO Open](https://onco.cc/journals/esmo-open/)

---
JSON: https://onco.cc/api/v1/entities/laurence-albiges.json